GoAI
Get started
Embecta Corp. logo

Embecta Corp.

EMBC

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$5.23

−$0.24 · -4.39%

Aug 21, 4:00 PM ET

EMBC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

85

Deep Value

Momentum

19

Strong Down

Sentiment

64

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Devdatt Kurdikar
Listed since
Mar 22, 2022
Employees
1,850

Market position

Day range

Current $5.23

52-week range

Current $5.23

Open
$5.455
Previous close
$5.47
Volume
1.13M
0.51× average
Average volume
2.2M
Average daily volume
Market cap
310.28M USD
Beta
0.79
Market reference 1
50-day average
$3.6989
+41.39% above average
200-day average
$8.1415
-35.76% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.03B USD
EV / EBITDA
6.88×
Earnings yield
11.60%
Free cash flow yield
22.17%

Profitability & efficiency

Return on equity
-14.65%
Return on assets
8.75%
Return on invested capital
27.36%

Financial health

Current ratio
2.41×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%50%25%0%Gross margin, FY2021: 68.67%Gross margin, FY2022: 68.61%Gross margin, FY2023: 66.91%Gross margin, FY2024: 64.90%Gross margin, FY2025: 62.89%Operating margin, FY2021: 42.23%Operating margin, FY2022: 33.47%Operating margin, FY2023: 20.49%Operating margin, FY2024: 15.51%Operating margin, FY2025: 30.48%Net margin, FY2021: 35.61%Net margin, FY2022: 19.80%Net margin, FY2023: 6.28%Net margin, FY2024: 6.97%Net margin, FY2025: 8.83%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.67%. Gross margin FY2022 68.61%. Gross margin FY2023 66.91%. Gross margin FY2024 64.90%. Gross margin FY2025 62.89%. Operating margin FY2021 42.23%. Operating margin FY2022 33.47%. Operating margin FY2023 20.49%. Operating margin FY2024 15.51%. Operating margin FY2025 30.48%. Net margin FY2021 35.61%. Net margin FY2022 19.80%. Net margin FY2023 6.28%. Net margin FY2024 6.97%. Net margin FY2025 8.83%.

Income trends

Revenue

1.08B USD-3.80%

Operating income

329.3M USD+89.04%

Net income

95.4M USD+21.84%
Income trends across reported periods1.27B USD836.62M USD398.78M USD−39.06M USDRevenue, FY2021: 1.17B USDRevenue, FY2022: 1.13B USDRevenue, FY2023: 1.12B USDRevenue, FY2024: 1.12B USDRevenue, FY2025: 1.08B USDOperating income, FY2021: 492M USDOperating income, FY2022: 378.1M USDOperating income, FY2023: 229.6M USDOperating income, FY2024: 174.2M USDOperating income, FY2025: 329.3M USDNet income, FY2021: 414.8M USDNet income, FY2022: 223.6M USDNet income, FY2023: 70.4M USDNet income, FY2024: 78.3M USDNet income, FY2025: 95.4M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.17B USD. Revenue FY2022 1.13B USD. Revenue FY2023 1.12B USD. Revenue FY2024 1.12B USD. Revenue FY2025 1.08B USD. Operating income FY2021 492M USD. Operating income FY2022 378.1M USD. Operating income FY2023 229.6M USD. Operating income FY2024 174.2M USD. Operating income FY2025 329.3M USD. Net income FY2021 414.8M USD. Net income FY2022 223.6M USD. Net income FY2023 70.4M USD. Net income FY2024 78.3M USD. Net income FY2025 95.4M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.08B USD1.12B USD1.12B USD1.13B USD1.17B USD
Cost of goods sold400.9M USD394.2M USD370.9M USD354.6M USD365M USD
Gross profit679.5M USD728.9M USD749.9M USD774.9M USD800M USD
Research and development21.5M USD78.8M USD85.2M USD65M USD63M USD
Selling, general, and administrative331.4M USD365.1M USD341.3M USD294.8M USD240.3M USD
Operating expenses350.2M USD554.7M USD520.3M USD396.8M USD308M USD
Interest expense107.3M USD112.3M USD107M USD46.2M USD—
Depreciation and amortization51.1M USD42.5M USD32.7M USD31.7M USD38M USD
Operating income329.3M USD174.2M USD229.6M USD378.1M USD492M USD
Net income95.4M USD78.3M USD70.4M USD223.6M USD414.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+38.14%
11 comparable reports
Latest EPS result
0.56
Estimate 0.27 · Beat by 110.68%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.190.870.550.23Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 0.65, estimate 0.45, surprise +44.44%, Beat. Q2 2025, reported May 9, 2025: actual 0.7, estimate 0.66, surprise +6.06%, Beat. Q3 2025, reported Aug 8, 2025: actual 1.12, estimate 0.455, surprise +146.15%, Beat. Q4 2025, reported Nov 25, 2025: actual 0.5, estimate 0.7, surprise -28.57%, Miss. Q1 2026, reported Feb 5, 2026: actual 0.71, estimate 0.67, surprise +5.97%, Beat. Q2 2026, reported May 5, 2026: actual 0.27, estimate 0.42, surprise -35.71%, Miss. Q3 2026, reported Aug 7, 2026: actual 0.56, estimate 0.266, surprise +110.68%, Beat. Q4 2026, reported Nov 24, 2026: actual —, estimate 0.31, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates307.32M274.87M242.43M209.98MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 261.9M USD, estimate 264.4M USD, surprise -0.95%, Miss. Q2 2025, reported May 9, 2025: actual 259M USD, estimate 278.78M USD, surprise -7.09%, Miss. Q3 2025, reported Aug 8, 2025: actual 295.5M USD, estimate 265.66M USD, surprise +11.23%, Beat. Q4 2025, reported Nov 25, 2025: actual 264M USD, estimate 258.2M USD, surprise +2.25%, Beat. Q1 2026, reported Feb 5, 2026: actual 261.2M USD, estimate 258.07M USD, surprise +1.21%, Beat. Q2 2026, reported May 5, 2026: actual 221.8M USD, estimate 235.67M USD, surprise -5.89%, Miss. Q3 2026, reported Aug 7, 2026: actual 271.7M USD, estimate 254.53M USD, surprise +6.75%, Beat. Q4 2026, reported Nov 24, 2026: actual —, estimate 269.71M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

4 institutions
B of A SecuritiesmaintainUnderperform

EMBC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding EMBC

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.8M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.67M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.09M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.55M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab Fundamental U.S. Small Company Index ETF logoSchwab Fundamental U.S. Small Company Index ETFFNDA
Market value
2.25M
Weight
0.02%
AUM
9.26B USD
Expense ratio
0.25%
Price / 1D
$37.73+0.75%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.52M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.21M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Inspire Small/Mid Cap ETF logoInspire Small/Mid Cap ETFISMD
Market value
1.07M
Weight
0.31%
AUM
349.35M USD
Expense ratio
0.53%
Price / 1D
$49.57+0.36%

Continue in GoAI

Research EMBC

research.disclaimer